SSII

Company Overview — What Does SS Innovations International, Inc. Do?

AVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida. SS Innovations International, Inc. (SSII) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO N/A and employs approximately 4 people. With a market capitalization of $971M, SSII is one of the notable companies in the Healthcare sector.

SS Innovations International, Inc. (SSII) Stock Rating — Reduce (April 2026)

As of April 2026, SS Innovations International, Inc. receives a Reduce rating with a composite score of 30.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.SSII ranks #3,214 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, SS Innovations International, Inc. ranks #485 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SSII Stock Price and 52-Week Range

SS Innovations International, Inc. (SSII) currently trades at $4.30. The stock lost $0.22 (4.9%) in the most recent trading session. The 52-week high for SSII is $22.42, which means the stock is currently trading -80.8% from its annual peak. The 52-week low is $3.02, putting the stock 42.6% above its annual trough. Recent trading volume was 35K shares, suggesting relatively thin trading activity.

Is SSII Overvalued or Undervalued? — Valuation Analysis

SS Innovations International, Inc. (SSII) carries a value factor score of 34/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 25.03x, versus the sector average of 2.75x. The price-to-sales ratio is 29.58x, compared to 1.66x for the average Healthcare stock.

At current multiples, SS Innovations International, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

SS Innovations International, Inc. Profitability — ROE, Margins, and Quality Score

SS Innovations International, Inc. (SSII) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -33.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -17.4% versus the sector average of -33.1%.

On a margin basis, SS Innovations International, Inc. reports gross margins of 45.3%, compared to 71.5% for the sector. The operating margin is -50.5% (sector: -66.1%). Net profit margin stands at -54.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 192.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SSII Debt, Balance Sheet, and Financial Health

SS Innovations International, Inc. has a debt-to-equity ratio of 94.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.86x, suggesting adequate working capital coverage. Total debt on the balance sheet is $2M. Cash and equivalents stand at $6M.

SSII has a beta of 0.12, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for SS Innovations International, Inc. is 37/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

SS Innovations International, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, SS Innovations International, Inc. reported revenue of $32M and earnings per share (EPS) of $-0.06. Net income for the quarter was $-13M. Gross margin was 45.3%. Operating income came in at $-11M.

In FY 2025, SS Innovations International, Inc. reported revenue of $42M and earnings per share (EPS) of $-0.06. Net income for the quarter was $-12M. Gross margin was 46.0%. Revenue grew 105.7% year-over-year compared to FY 2024. Operating income came in at $-8M.

In Q3 2025, SS Innovations International, Inc. reported revenue of $13M and earnings per share (EPS) of $-0.02. Net income for the quarter was $-4M. Gross margin was 48.0%. Revenue grew 192.5% year-over-year compared to Q3 2024. Operating income came in at $-2M.

In Q2 2025, SS Innovations International, Inc. reported revenue of $10M and earnings per share (EPS) of $0.00. Net income for the quarter was $-256,691. Gross margin was 59.2%. Revenue grew 128.0% year-over-year compared to Q2 2024. Operating income came in at $97,014.

Over the past 8 quarters, SS Innovations International, Inc. has demonstrated a growth trajectory, with revenue expanding from $4M to $32M. Investors analyzing SSII stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SSII Dividend Yield and Income Analysis

SS Innovations International, Inc. (SSII) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SSII Momentum and Technical Analysis Profile

SS Innovations International, Inc. (SSII) has a momentum factor score of 21/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 68/100 reflects moderate short selling activity.

SSII vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, SS Innovations International, Inc. (SSII) ranks #485 out of 838 stocks based on the Blank Capital composite score. This places SSII in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SSII against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SSII vs S&P 500 (SPY) comparison to assess how SS Innovations International, Inc. stacks up against the broader market across all factor dimensions.

SSII Next Earnings Date

No upcoming earnings date has been announced for SS Innovations International, Inc. (SSII) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SSII? — Investment Thesis Summary

The quantitative profile for SS Innovations International, Inc. suggests caution. The quality score of 24/100 flags below-average profitability. The value score of 34/100 indicates premium valuation. Momentum is weak at 21/100, a headwind for near-term performance. High volatility (stability score 37/100) increases portfolio risk.

In summary, SS Innovations International, Inc. (SSII) earns a Reduce rating with a composite score of 30.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SSII stock.

Related Resources for SSII Investors

Explore more research and tools: SSII vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SSII head-to-head with peers: SSII vs AZN, SSII vs SLGL, SSII vs VMD.